These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23243212)

  • 1. Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.
    Dhaun N; Melville V; Blackwell S; Talwar DK; Johnston NR; Goddard J; Webb DJ
    J Am Soc Nephrol; 2013 Jan; 24(1):31-6. PubMed ID: 23243212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism.
    Dhaun N; Yuzugulen J; Kimmitt RA; Wood EG; Chariyavilaskul P; MacIntyre IM; Goddard J; Webb DJ; Corder R
    J Am Heart Assoc; 2015 Mar; 4(3):e001624. PubMed ID: 25801761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease.
    Dhaun N; MacIntyre IM; Kerr D; Melville V; Johnston NR; Haughie S; Goddard J; Webb DJ
    Hypertension; 2011 Apr; 57(4):772-9. PubMed ID: 21357275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diurnal variation in blood pressure and arterial stiffness in chronic kidney disease: the role of endothelin-1.
    Dhaun N; Moorhouse R; MacIntyre IM; Melville V; Oosthuyzen W; Kimmitt RA; Brown KE; Kennedy ED; Goddard J; Webb DJ
    Hypertension; 2014 Aug; 64(2):296-304. PubMed ID: 24890823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease.
    Dhaun N; Macintyre IM; Melville V; Lilitkarntakul P; Johnston NR; Goddard J; Webb DJ
    Hypertension; 2009 Jul; 54(1):113-9. PubMed ID: 19506099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease.
    Farrah TE; Anand A; Gallacher PJ; Kimmitt R; Carter E; Dear JW; Mills NL; Webb DJ; Dhaun N
    Hypertension; 2019 Aug; 74(2):323-330. PubMed ID: 31177906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney.
    Dhaun N; MacIntyre IM; Bellamy CO; Kluth DC
    Am J Kidney Dis; 2009 Oct; 54(4):726-31. PubMed ID: 19376621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease.
    Larivière R; Gauthier-Bastien A; Ung RV; St-Hilaire J; Mac-Way F; Richard DE; Agharazii M
    J Hypertens; 2017 Feb; 35(2):376-384. PubMed ID: 28005706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the best method of proteinuria measurement in clinical trials of endothelin receptor antagonists?
    Towler JD; Dhaun N; MacDougall M; Melville V; Goddard J; Webb DJ
    Life Sci; 2012 Oct; 91(13-14):733-8. PubMed ID: 22406074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
    Kohan DE; Pollock DM
    Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low urinary citrulline/arginine ratio associated with blood pressure abnormalities and arterial stiffness in childhood chronic kidney disease.
    Lin IC; Hsu CN; Lo MH; Chien SJ; Tain YL
    J Am Soc Hypertens; 2016 Feb; 10(2):115-23. PubMed ID: 26712087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects.
    Stavros F; Kramer WG; Wilkins MR
    Br J Clin Pharmacol; 2010 Jan; 69(1):23-6. PubMed ID: 20078609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease--a randomized trial.
    Frimodt-Møller M; Kamper AL; Strandgaard S; Kreiner S; Nielsen AH
    PLoS One; 2012; 7(7):e41757. PubMed ID: 22860014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans.
    Honing MLH; Hijmering ML; Ballard DE; Yang YP; Padley RJ; Morrison PJ; Rabelink TJ
    J Am Soc Nephrol; 2000 Aug; 11(8):1498-1504. PubMed ID: 10906163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin antagonism in patients with nondiabetic chronic kidney disease.
    Dhaun N; Goddard J; Webb DJ
    Contrib Nephrol; 2011; 172():243-254. PubMed ID: 21894004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients.
    Levin A; Perry T; De Zoysa P; Sigrist MK; Humphries K; Tang M; Djurdjev O
    BMC Cardiovasc Disord; 2014 Nov; 14():156. PubMed ID: 25381032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifestyle modification decreases arterial stiffness and plasma asymmetric dimethylarginine level in overweight and obese men.
    Maeda S; Miyaki A; Kumagai H; Eto M; So R; Tanaka K; Ajisaka R
    Coron Artery Dis; 2013 Nov; 24(7):583-8. PubMed ID: 23881175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
    MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
    Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency.
    Törmänen S; Pörsti I; Lakkisto P; Tikkanen I; Niemelä O; Paavonen T; Mustonen J; Eräranta A
    BMC Nephrol; 2017 Oct; 18(1):323. PubMed ID: 29078759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats.
    Mirabito Colafella KM; Neves KB; Montezano AC; Garrelds IM; van Veghel R; de Vries R; Uijl E; Baelde HJ; van den Meiracker AH; Touyz RM; Danser AHJ; Versmissen J
    Cardiovasc Res; 2020 Aug; 116(10):1779-1790. PubMed ID: 31593221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.